Kate Hardey

Since joining Kirkland, Kate has been involved in the following matters:

• Phibro Animal Health Corporation (NASDAQ: PAHC) in its pending $350 million acquisition of medicated feed additive and water soluble product portfolios from Zoetis (NYSE: ZTS).
• Wind Point Partners in the sale of Handgards, a provider of disposable food safety and hygiene-oriented products for the foodservice industry, to Wynnchurch Capital.
• Ingersoll Rand Inc., a global provider of mission-critical flow creation and industrial solutions, on the proposed $2.325 billion acquisition of ILC Dover from New Mountain Capital.
• CapVest Partners-backed Calyx in its $115 million acquisition of Invicro, a provider of imaging biomarker services, from REALM IDx.
• Montagu in its proposed acquisition of Johnson Matthey Plc’s (LSE: JMAT) medical device components business.
• Carlisle Companies (NYSE: CSL) in its pending $2.025 billion sale of Carlisle Interconnect Technologies to Amphenol (NYSE: APH).
• AbbVie (NYSE: ABBV) in its pending $8.7 billion acquisition of Cerevel Therapeutics (NASDAQ: CERE), a neuroscience drug company.
• SKKY Partners in its investment in TRUFF, a brand of premium condiments and truffle infused products.
• GTCR in its $180 million acquisition of Cloudbreak Health, LLC, a leading provider of tech-enabled, healthcare-focused language interpretation services.
• Nordic Capital in its acquisition of IntegriChain, a platform for pharma commercialization and market access, from Accel-KKR.
• KKR- and Everstone Capital-backed Slayback Pharma, a provider of generic and specialty pharmaceutical products, in its sale to Azurity Pharmaceuticals.
• Eli Lilly and Company (NYSE: LLY) in its $1.4 billion acquisition of POINT Biopharma (NASDAQ: PNT), a radiopharmaceutical company.
• L Catterton in its $680 million acquisition of Thorne HealthTech (NASDAQ: THRN), a provider of health and wellness solutions.
• FFL Partners in its investment in Johnson County Clin-Trials, a clinical research site platform serving pharmaceutical and biotechnology companies and contract research organizations.

Prior to joining Kirkland, Kate was involved in the following matters:

• Represented lender in healthcare review to support Cerberus $400 million acquisition of Abry’s Lighthouse Autism Center.
• Advised B. Riley Securities Inc. and Roth Capital Partners in a $35.2 million IPO of Journey Medical Corp.
• Representation of Alliance Global Partners (AGP), in connection with the launch of an at-the-market program in which AGP served as the placement agent to ProPhase Labs, In. (NASDAQ: PRPH), a manufacturing and marketing company with experience with OTC consumer healthcare products and dietary supplements.
• Representation of National Securities Corp., acting as exclusive placement agent, in connection with a private offering and sale of preferred stock by Cyprium Therapeutics, Inc., a clinical-state biopharmaceutical company.

Partner, McGuireWoods LLP

Senior Counsel – Healthcare Regulatory, GE Capital Healthcare Financial Services

Hospital Counsel, MedStar Health

Kate served as a volunteer board member for the Domestic Violence Legal Empowerment and Appeals Project (DV LEAP) from January 2014 to June 2022. DV LEAP provides a stronger voice for justice by fighting to overturn unjust trial court outcomes, advancing legal protections for victims of domestic violence and their children through expert appellate advocacy, training lawyers, psychologists and judges on best practices, and spearheading domestic violence litigation in the Supreme Court.